DOCSLIB.ORG

Information on Progestogen-Only Contraceptive Pills (Minipill)

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Information on Progestogen-Only Contraceptive Pills (Minipill) 4. Missed Pill Management (Information apply to desogestrel contraceptive pill only) Information on ●● Delay taking 1 pill for less than 12 hours Please take the delayed pill immediately Progestogen-only Take the remaining pills as your usual schedule ●● Delay taking pill/ pills for more than 12 hours Contraceptive Pills Please take the delayed pill immediately Take the remaining pills as your usual schedule (Minipill) Use condom as backup contraception in the coming 7 days for protection against pregnancy. Please return to Maternal and Child Health Centre as soon as possible for counseling and assessing the need for emergency contraception. 5. Taking other medication ●● Please inform your doctor you are taking oral contraceptive pills before taking other medication, as some medication may affect the contraceptive effect of contraceptive pills. If you have any queries, please return to the Maternal and Child Health Centre for advice. Family Health Service Website: www.fhs.gov.hk FHS-WH 2A (Rev Jun 2020) 24-hour Information Hotline: 2112 9900 Printed by the Government Logistics Department DEPARTMENT OF HEALTH 1. Background Information 3. Side Effects ●● Progestogen-only contraceptive pills (minipill) ●● You may have bleeding contain one synthetic hormone - progestogen. irregularity, diminished It works by inhibiting ovulation, interfering sperm menses flow or no transportation and embryo implantation. menses which is related ●● It is highly effective and the failure rate is less to the hormonal effect than 1% if taken properly. of the progestogen. ● ● It is most suitable for breastfeeding mothers as ●● Other common side it does not affect breastmilk production. effects including breast ●● It provides a choice for women tenderness, nauseas, who cannot use combined acne, headaches and mood oral contraceptive pills for changes can be occurred at the medical or other reasons. initial period of use and usually subside within For example, women who the first few months. smoke or with diabetes ● mellitus, hypertension or ● Please seek medical assessment as soon as other illnesses that may be possible and tell your doctor you are using worsen by intake of Progestogen-only contraceptive pills, if you oestrogen. have the following symptoms: ●● Clients should consult a ■ Such as onset of severe headaches or doctor before migraine after starting the pills, fainting, rise commencing the pills. in blood pressure, weakness or tingling/ numbing sensation affecting one side or 2. Method of Administration one part of the body, yellowing of the skin ●● In general, women should commence the pills or whites of the eyes (jaundice), abdominal within the first 5 days of menses. pain, calf pain or severe chest pain. ●● If vomiting occurs within 3 hours of pill taking, ●● Please return to Maternal and Child Health take another pill as soon as possible to achieve Centre for assessment for suitability to continue sufficient contraceptive effect. your contraceptive pill, if you have the ●● If you have continued vomiting or following conditions: have a severe diarrhea, ■ Have any signs and symptoms of please use condom as pregnancy; a backup contraception during ■ Newly diagnosed diseases, e.g. heart your illness and plus 7 disease, stroke, diabetes, hyperlipidaemia, days after illness. thromboembolic disease, cancer or other ●● Pills should be taken newly diagnosed medical and surgical at the same time every day. diseases. 1. Background Information 3. Side Effects ●● Progestogen-only contraceptive pills (minipill) ●● You may have bleeding contain one synthetic hormone - progestogen. irregularity, diminished It works by inhibiting ovulation, interfering sperm menses flow or no transportation and embryo implantation. menses which is related ●● It is highly effective and the failure rate is less to the hormonal effect than 1% if taken properly. of the progestogen. ● ● It is most suitable for breastfeeding mothers as ●● Other common side it does not affect breastmilk production. effects including breast ●● It provides a choice for women tenderness, nauseas, who cannot use combined acne, headaches and mood oral contraceptive pills for changes can be occurred at the medical or other reasons. initial period of use and usually subside within For example, women who the first few months. smoke or with diabetes ● mellitus, hypertension or ● Please seek medical assessment as soon as other illnesses that may be possible and tell your doctor you are using worsen by intake of Progestogen-only contraceptive pills, if you oestrogen. have the following symptoms: ●● Clients should consult a ■ Such as onset of severe headaches or doctor before migraine after starting the pills, fainting, rise commencing the pills. in blood pressure, weakness or tingling/ numbing sensation affecting one side or 2. Method of Administration one part of the body, yellowing of the skin ●● In general, women should commence the pills or whites of the eyes (jaundice), abdominal within the first 5 days of menses. pain, calf pain or severe chest pain. ●● If vomiting occurs within 3 hours of pill taking, ●● Please return to Maternal and Child Health take another pill as soon as possible to achieve Centre for assessment for suitability to continue sufficient contraceptive effect. your contraceptive pill, if you have the ●● If you have continued vomiting or following conditions: have a severe diarrhea, ■ Have any signs and symptoms of please use condom as pregnancy; a backup contraception during ■ Newly diagnosed diseases, e.g. heart your illness and plus 7 disease, stroke, diabetes, hyperlipidaemia, days after illness. thromboembolic disease, cancer or other ●● Pills should be taken newly diagnosed medical and surgical at the same time every day. diseases. 4. Missed Pill Management (Information apply to desogestrel contraceptive pill only) Information on ●● Delay taking 1 pill for less than 12 hours Please take the delayed pill immediately Progestogen-only Take the remaining pills as your usual schedule ●● Delay taking pill/ pills for more than 12 hours Contraceptive Pills Please take the delayed pill immediately Take the remaining pills as your usual schedule (Minipill) Use condom as backup contraception in the coming 7 days for protection against pregnancy. Please return to Maternal and Child Health Centre as soon as possible for counseling and assessing the need for emergency contraception. 5. Taking other medication ●● Please inform your doctor you are taking oral contraceptive pills before taking other medication, as some medication may affect the contraceptive effect of contraceptive pills. If you have any queries, please return to the Maternal and Child Health Centre for advice. Family Health Service Website: www.fhs.gov.hk FHS-WH 2A (Rev Jun 2020) 24-hour Information Hotline: 2112 9900 Printed by the Government Logistics Department DEPARTMENT OF HEALTH.
Load more

Recommended publications
  • 35 Cyproterone Acetate and Ethinyl Estradiol Tablets 2 Mg/0
    PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION PrCYESTRA®-35 cyproterone acetate and ethinyl estradiol tablets 2 mg/0.035 mg THERAPEUTIC CLASSIFICATION Acne Therapy Paladin Labs Inc. Date of Preparation: 100 Alexis Nihon Blvd, Suite 600 January 17, 2019 St-Laurent, Quebec H4M 2P2 Version: 6.0 Control # 223341 _____________________________________________________________________________________________ CYESTRA-35 Product Monograph Page 1 of 48 Table of Contents PART I: HEALTH PROFESSIONAL INFORMATION ....................................................................... 3 SUMMARY PRODUCT INFORMATION ............................................................................................. 3 INDICATION AND CLINICAL USE ..................................................................................................... 3 CONTRAINDICATIONS ........................................................................................................................ 3 WARNINGS AND PRECAUTIONS ....................................................................................................... 4 ADVERSE REACTIONS ....................................................................................................................... 13 DRUG INTERACTIONS ....................................................................................................................... 16 DOSAGE AND ADMINISTRATION ................................................................................................ 20 OVERDOSAGE ....................................................................................................................................
    [Show full text]
  • The Progestogen Only Pill
    The Progestogen Only Pill Mini-pill or POP A service provided by page 2 of 8 How does the progestogen only pill (POP) work? The progestogen only pill mainly works by thickening the mucus you produce from your cervix. This makes it more difficult for sperm to get to the egg. It can also sometimes stop your ovaries from producing an egg (ovulation). How effective is the pill? The effectiveness of the pill depends on the woman taking it. At best it is over 98% effective (when no pills are missed). However failure rates can be much higher (9-15%) if women do not remember to take their pill properly. Missed pills can lead to pregnancy. Advantages of the POP • It doesn’t interfere with sex. • You can use it whilst you are breastfeeding. • It is useful if you cannot take oestrogen (the hormone contained in the combined oral contraceptive) • Can be used at any age even if you smoke and are over 35 years of age. • It may help with premenstrual symptoms and painful periods. page 3 of 8 Disadvantages of the POP • You have to remember to take your pill at the same time every day. • Your periods may become irregular or even stop altogether on the POP, this is not dangerous but if you miss a period you need to check that you are not pregnant by coming to clinic for a pregnancy test. • You may get some temporary side effects, such as spotty skin, breast tenderness and mood changes, though these should stop within a few months.
    [Show full text]
  • Hormonal Treatment Strategies Tailored to Non-Binary Transgender Individuals
    Journal of Clinical Medicine Review Hormonal Treatment Strategies Tailored to Non-Binary Transgender Individuals Carlotta Cocchetti 1, Jiska Ristori 1, Alessia Romani 1, Mario Maggi 2 and Alessandra Daphne Fisher 1,* 1 Andrology, Women’s Endocrinology and Gender Incongruence Unit, Florence University Hospital, 50139 Florence, Italy; [email protected] (C.C); jiska.ristori@unifi.it (J.R.); [email protected] (A.R.) 2 Department of Experimental, Clinical and Biomedical Sciences, Careggi University Hospital, 50139 Florence, Italy; [email protected]fi.it * Correspondence: fi[email protected] Received: 16 April 2020; Accepted: 18 May 2020; Published: 26 May 2020 Abstract: Introduction: To date no standardized hormonal treatment protocols for non-binary transgender individuals have been described in the literature and there is a lack of data regarding their efficacy and safety. Objectives: To suggest possible treatment strategies for non-binary transgender individuals with non-standardized requests and to emphasize the importance of a personalized clinical approach. Methods: A narrative review of pertinent literature on gender-affirming hormonal treatment in transgender persons was performed using PubMed. Results: New hormonal treatment regimens outside those reported in current guidelines should be considered for non-binary transgender individuals, in order to improve psychological well-being and quality of life. In the present review we suggested the use of hormonal and non-hormonal compounds, which—based on their mechanism of action—could be used in these cases depending on clients’ requests. Conclusion: Requests for an individualized hormonal treatment in non-binary transgender individuals represent a future challenge for professionals managing transgender health care. For each case, clinicians should balance the benefits and risks of a personalized non-standardized treatment, actively involving the person in decisions regarding hormonal treatment.
    [Show full text]
  • SLINDA® (DROSPIRENONE 4 Mg) TABLETS
    SLINDA® (DROSPIRENONE 4 mg) TABLETS AUSTRALIAN PRODUCT INFORMATION AUSTRALIAN PRODUCT 4.2 Dose And Method Of INFORMATION Administration SLINDA® (DROSPIRENONE) TABLETS Dose How to take SLINDA 1. NAME OF THE MEDICINE One tablet is to be taken daily for 28 Drospirenone consecutive days; one white active tablet daily during the first 24 days and one green inactive tablet 2. QUALITATIVE daily during the 4 following days. Tablets must be taken every day, at about AND QUANTITATIVE the same time of the day, so that the COMPOSITION interval between two tablets is always 24 hours. Tablets should be taken in White active film-coated tablets: the order shown on the blister. Stickers Each tablet contains 4 mg of marked with the 7 days of the week are drospirenone. provided. The patient should choose the sticker that starts with the day they Green placebo film-coated tablets: begin taking the tablets and stick it on The tablet does not contain active the blister. substances. The first tablet of the treatment should Excipient(s) with known effect: be taken on the first day of menstrual Each white active film-coated tablet bleeding. Thereafter tablet taking contains 17.5 mg of lactose. is continuous. A subsequent pack is started immediately after finishing the Each green placebo film-coated tablet previous pack, without a break in daily contains 55.5 mg of lactose monohydrate. tablet intake. For the full list of excipients, see section How to start SLINDA 6.1 List of Excipients. No preceding hormonal contraceptive use (in the past month) Tablet-taking has to start on day 1 of the 3.
    [Show full text]
  • Desogestrel-Only Pill (Cerazette)
    J Fam Plann Reprod Health Care: first published as 10.1783/147118903101197593 on 1 July 2003. Downloaded from Faculty of Family Planning and Reproductive Health Care Clinical Effectiveness Unit A unit funded by the FFPRHC and supported by the University of Aberdeen and SPCERH to provide guidance on evidence-based practice New Product Review (April 2003) Desogestrel-only Pill (Cerazette) Journal of Family Planning and Reproductive Health Care 2003; 29(3): 162–164 Evidence from a randomised trial has shown that a 75 mg (microgrammes) desogestrel pill inhibits ovulation in 97% of cycles. Thus, on theoretical grounds, we would expect the desogestrel pill to be more effective than existing progestogen- only pills (POPs). However, Pearl indices from clinical trials comparing it to a levonorgestrel POP were not significantly different. Therefore an evidence-based recommendation cannot be made that the desogestrel pill is different from other POPs in terms of efficacy, nor that it is similar to combined oral contraception (COC) in this respect. An evidence-based recommendation can be made that the desogestrel-only pill is similar to other POPs in terms of side effects and acceptability. The desogestrel-only pill is not recommended as an alternative to COC in routine practice, but provides a useful alternative for women who require oestrogen-free contraception. In clinical trials: l Ovulation was inhibited in 97% of cycles at 7 and 12 months after initiation. l The Pearl index was 0.41 per 100 woman-years, which was not significantly different from a levonorgestrel-only pill. However, the trial providing these data was too small to detect a clinically important difference.
    [Show full text]
  • Dose Response Effect of Cyclical Medroxyprogesterone on Blood Pressure in Postmenopausal Women
    Journal of Human Hypertension (2001) 15, 313–321 2001 Nature Publishing Group All rights reserved 0950-9240/01 $15.00 www.nature.com/jhh ORIGINAL ARTICLE Dose response effect of cyclical medroxyprogesterone on blood pressure in postmenopausal women PJ Harvey1, D Molloy2, J Upton2 and LM Wing1 Departments of 1Clinical Pharmacology and 2Medicine, Flinders University of South Australia, Bedford Park, Adelaide, South Australia, Australia 5042 Objective: This study was designed to compare with mean values of weeks 3 and 4 of each phase used for placebo the dose-response effect of cyclical doses of analysis. Ambulatory BP was performed in the final the C21 progestogen, medroxyprogesterone acetate week of each phase. (MPA) on blood pressure (BP) when administered to Results: Compared with the placebo phase, end of normotensive postmenopausal women receiving a fixed phase clinic BP was unchanged by any of the proges- mid-range daily dose of conjugated equine oestrogen togen treatments. There was a dose-dependent (CEE). decrease in ambulatory daytime diastolic and mean Materials and methods: Twenty normotensive post- arterial BP with the progestogen treatments compared menopausal women (median age 53 years) participated with placebo (P Ͻ 0.05). in the study which used a double-blind crossover Conclusion: In a regimen of postmenopausal hormone design. There were four randomised treatment phases, replacement therapy with a fixed mid-range daily dose each of 4 weeks duration. The four blinded treatments of CEE combined with a cyclical regimen of a C21 pro- were MPA 2.5 mg, MPA 5 mg, MPA 10 mg and matching gestogen spanning the current clinical dose range, the placebo, taken for the last 14 days of each 28 day treat- progestogen has either no effect or a small dose-depen- ment cycle.
    [Show full text]
  • Combined Estrogen–Progestogen Menopausal Therapy
    COMBINED ESTROGEN–PROGESTOGEN MENOPAUSAL THERAPY Combined estrogen–progestogen menopausal therapy was considered by previous IARC Working Groups in 1998 and 2005 (IARC, 1999, 2007). Since that time, new data have become available, these have been incorporated into the Monograph, and taken into consideration in the present evaluation. 1. Exposure Data 1.1.2 Progestogens (a) Chlormadinone acetate Combined estrogen–progestogen meno- Chem. Abstr. Serv. Reg. No.: 302-22-7 pausal therapy involves the co-administration Chem. Abstr. Name: 17-(Acetyloxy)-6-chlo- of an estrogen and a progestogen to peri- or ropregna-4,6-diene-3,20-dione menopausal women. The use of estrogens with IUPAC Systematic Name: 6-Chloro-17-hy- progestogens has been recommended to prevent droxypregna-4,6-diene-3,20-dione, acetate the estrogen-associated risk of endometrial Synonyms: 17α-Acetoxy-6-chloro-4,6- cancer. Evidence from the Women’s Health pregnadiene-3,20-dione; 6-chloro-Δ6-17- Initiative (WHI) of adverse effects from the use acetoxyprogesterone; 6-chloro-Δ6-[17α] of a continuous combined estrogen–progestogen acetoxyprogesterone has affected prescribing. Patterns of exposure Structural and molecular formulae, and relative are also changing rapidly as the use of hormonal molecular mass therapy declines, the indications are restricted, O CH and the duration of the therapy is reduced (IARC, 3 C 2007). CH3 CH3 O C 1.1 Identification of the agents CH3 H O 1.1.1 Estrogens HH For Estrogens, see the Monograph on O Estrogen-only Menopausal Therapy in this Cl volume. C23H29ClO4 Relative molecular mass: 404.9 249 IARC MONOGRAPHS – 100A (b) Cyproterone acetate Structural and molecular formulae, and relative Chem.
    [Show full text]
  • Australian Public Assessment Report for Progesterone
    Australian Public Assessment Report for Progesterone Proprietary Product Name: Prometrium / Utrogestan Sponsor: Besins Healthcare Australia Pty Ltd June 2017 Therapeutic Goods Administration About the Therapeutic Goods Administration (TGA) • The Therapeutic Goods Administration (TGA) is part of the Australian Government Department of Health and is responsible for regulating medicines and medical devices. • The TGA administers the Therapeutic Goods Act 1989 (the Act), applying a risk management approach designed to ensure therapeutic goods supplied in Australia meet acceptable standards of quality, safety and efficacy (performance) when necessary. • The work of the TGA is based on applying scientific and clinical expertise to decision- making, to ensure that the benefits to consumers outweigh any risks associated with the use of medicines and medical devices. • The TGA relies on the public, healthcare professionals and industry to report problems with medicines or medical devices. TGA investigates reports received by it to determine any necessary regulatory action. • To report a problem with a medicine or medical device, please see the information on the TGA website <https://www.tga.gov.au>. About AusPARs • An Australian Public Assessment Report (AusPAR) provides information about the evaluation of a prescription medicine and the considerations that led the TGA to approve or not approve a prescription medicine submission. • AusPARs are prepared and published by the TGA. • An AusPAR is prepared for submissions that relate to new chemical entities, generic medicines, major variations and extensions of indications. • An AusPAR is a static document; it provides information that relates to a submission at a particular point in time. • A new AusPAR will be developed to reflect changes to indications and/or major variations to a prescription medicine subject to evaluation by the TGA.
    [Show full text]
  • Progestogen Only Pills Sal Roberts RN RM Msc NDSRH PGA Med Ed (SRH) FRT Progestogen Only Contraception
    Progestogen Only Pills Sal Roberts RN RM MSc NDSRH PGA Med Ed (SRH) FRT Progestogen Only Contraception • Implant • Pills • Injectables POC • No restrictions to use based purely on age • Can be used during lactation • Suitable for women with contraindications to estrogen containing contraceptives • No restrictions to use based purely on smoking history POP POPs can be divided into two categories: • Those that work primarily by a cervical mucus effect • Those that work primarily by inhibiting ovulation POP POPs That Work Primarily by a Cervical Mucus Effect: • primary mode of action is to cause thickening of cervical mucus, inhibiting sperm penetration into the upper reproductive tract • contain either norethisterone 350 μg (MicronorTM, NoridayTM) or levonorgestrel 30 μg (NorgestonTM) • referred to as traditional POPs • must be taken within three hours of the same time every day POP POPs That Work Primarily by Inhibiting Ovulation: • Desogestrel (DSG)-containing POPs work predominantly by suppressing ovulation • more effective than traditional POPs and may be less likely to be associated with follicular cysts and ectopic pregnancy • should be noted that ectopic pregnancy risk is lower with any type of POP than when using no contraception at all • appropriate for use for younger women or those with a history of symptomatic simple ovarian cysts • must be taken within 12 hours of the same time every day POP How effective?? • With consistent and correct use (i.e. 'perfect' use) the failure rate is <1%. However, 'typical' use gives a much higher failure rate of 8%. • No need for 2 pills for heavy women POP Suitability: As with all contraceptives, the clinician should take a full medical history to identify any conditions that fall within the UKMEC categories 3 or 4.
    [Show full text]
  • Dosage and Administration
    HGDS"'FG ·-···--··-· ..---- ·---·' .. e ·--­··---····~·----- 133 Molesworth Street PO Box5013 Wellington 6140 New Zealand T +64 4 496 2000 1 February 2019 Response to your request for official information I refer to your request of 4 January 2019 to the Ministry of Health (the Ministry), under the Official Information Act 1982 (the Act), for. "I wish to request the following information regarding (the now lapsed) Aldactone, film coated tablets, spironolactone 25 mg and 100mg (TTS0-1764, 1764a): • Please provide a copy of the most recent datasheet (approved in a CMN or notified ina SACN). • Please provide a copy of the most recent primary and secondary labelling (approved in a CMN or notified in a SACN). • Please advise if the approved NZ labelling included an ARTG number." Information held by the Ministry relating to your request is itemised below, with copies of documents attached. Attachment Details and decision number - Data sheet for Aldactone 25 mg and Aldactone 100 mg. 1 Information released in full. Copy of the primary and secondary labelling for Aldactone 25 mg and 2 Aldactone 100 mg. Information released in full. In response to part three of your request, the Ministry confirms that the approved secondary labelling for Aldactone 25 mg and Aldactone 100 mg in New Zealand contained Australian Register of Therapeutic Goods (ARTG) numbers: AUST R 68953 (Aldactone 25 mg) and AUST R 68954 (Aldactone 100 mg). I trust this information fulfils your request. Please note this response (with your personal details removed) may be published on the Ministry of Health website. Yours si r;,c;:arely ~ r,,..~-~/___/ / /..
    [Show full text]
  • Role of Progestogen in Hormone Therapy for Postmenopausal Women: Position Statement of the North American Menopause Society
    Menopause: The Journal of The North American Menopause Society Vol. 10, No. 2, pp. 113-132 DOI: 10.1097/01.GME.0000055879.45975.92 © 2003 The North American Menopause Society ࠗϱ Text printed on acid-free paper. POSITION STATEMENT Role of progestogen in hormone therapy for postmenopausal women: position statement of The North American Menopause Society ABSTRACT Objective: To create an evidence-based position statement regarding the role of progestogen in postmenopausal hormone therapy (estrogen plus a progestogen, or EPT) for the management of menopause-related symptoms. Design: NAMS followed the general principles established for evidence-based guidelines to create this document. Clinicians and researchers acknowledged to be experts in the field of post- menopausal hormone therapy were enlisted to review the evidence obtained from the medical literature and develop a position statement for approval by the NAMS Board of Trustees. Results: The primary role of progestogen in postmenopausal hormone therapy is endometrial protection. Unopposed estrogen therapy (ET) is associated with a significantly increased risk of endometrial hyperplasia and adenocarcinoma. Adding the appropriate dose and duration of pro- gestogen to ET has been shown to lower that risk to the level found in never-users of ET. The clinical goal of progestogen in EPT is to provide endometrial protection while maintaining estrogen benefits and minimizing progestogen-induced side effects, particularly uterine bleeding. EPT dis- continuance correlates with uterine bleeding—women with more days of amenorrhea have higher rates of continuance. All US Food and Drug Administration-approved progestogen formulations will provide endometrial protection if the dose and duration are adequate.
    [Show full text]
  • Progestogen-Only Emergency Contraception and Ectopic Pregnancy
    _________________________________________________________________________________________________________________ THENEDITORIALS AND NOW: TWENTY-FIVE YEARS AGO J Fam Plann Reprod Health Care: first published as 10.1783/147118903101197052 on 1 January 2003. Downloaded from _________________________________________________________________________________________________________________ Progestogen-only emergency contraception and ectopic pregnancy Pregnancies that occur in women using daily progestogen- all suggested the product had been taken as directed, and in only pills (POPs) are more likely to be ectopic than are 6/12 cases treatment commenced within 24 hours of pregnancies among users of most other contraceptive unprotected intercourse. In NZ, the CARM has received methods.1 This may be due to the mechanism of action of three reports of ectopic pregnancy following use of the POPs, which reduce the activity of fallopian tube cilia and progestogen-only emergency pill. In all three cases the alter tubal motility.1 By the same mechanism, it is possible treatment was taken as directed and in two cases it was that pregnancies following treatment failure with known to have started within 24 hours of unprotected progestogen-only emergency contraception (POEC) may be intercourse. In one report the doctor specified that the more likely to be ectopic. woman had no known risk factors for ectopic pregnancy and In the July 2002 issue of the Journal of Family Planning had previously had two normal pregnancies. Analysis of the and Reproductive Health Care, the first case report of WHO database identified a further three cases of ectopic ectopic pregnancy following failed postcoital POEC was pregnancy following treatment with levonorgestrel 0.75 mg published.2 During the last few months, medicines for emergency contraception.
    [Show full text]